Dosing accuracy of @entity506 and XXXX as treatment for @entity9231 @entity311 in Casamance, Senegal.

@entity1 @entity5427 @entity16944 @entity9231 @entity506 @entity311 @entity1445
OBJECTIVES: Several products of @entity506 plus @entity16944 ( @entity5427 + AQ) are being deployed in @entity311 -endemic countries for treating uncomplicated @entity9231 @entity311 but dosing accuracy and consequential effects on efficacy and tolerability have not been examined. METHODS: @entity1 with parasitologically confirmed, uncomplicated @entity9231 @entity311 were treated and followed by research teams or local health centre staff in Casamance, Senegal. @entity5427 + AQ was given as: (i) loose combination ( @entity5427 50 mg, AQ 200 mg), dosed on body weight, or (ii) co-blistered product ( @entity5427 50 mg, AQ 153 mg) dosed by weight or age. Target doses were: (i) @entity5427 4 (2-10) mg/kg/day and (ii) AQ 10 (7.5-15) mg/kg/day. @entity1 receiving therapeutic doses defined dosing accuracy. Treatment-emergent signs and symptoms (TESS) were recorded. RESULTS: A total of 3277 @entity1 were treated with loose (n = 1972, weight-dosed) or co-blistered (n = 1305, 962 age-dosed, 343 weight-dosed) @entity5427 + AQ by the research team (n = 966) or clinic staff (n = 2311). @entity5427 was dosed correctly in >99% with all regimens. Loose AQ by weight was 98% correct. The co-blister AQ overdosed 18% of @entity1 when dosed by age and underdosed 13% by weight. Low weight was an independent risk factor for @entity1445 . The co-blister had significantly more TESS than the loose product [117/1305 (9%) vs. 41/1972 (2%), relative risk = 4.3 (95% CI: 3.0-6.1, P < 0.0001)]. Age-based dosing accounted for the difference. TESS occurred mostly within one day (72%) and were mild or moderate (75%). CONCLUSION: @entity506 is easier to dose than AQ. Currently available age-dosed, co-blistered @entity5427 + AQ tends to @entity1445 AQ and is less well tolerated than loose tablets. It is not the optimal presentation of @entity5427 + AQ.
